Novocure Ltd (NVCR NASDAQ) stock market data APIs
$13.2663
0.12(0.9%)
as of November 2, 2026
Try our APIs with
free plan!
Novocure Ltd Financial Data Overview
Price chart is built with
Anychart
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Prev. Close
13.2663
Open
13.3863
High
13.702
Low
13.1649
52 wk Range
9.82-21.451
Market Cap
1 544 M
Shares Outstanding
117 M
Revenue
725 M
EPS
-0.09
Beta
1.084
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Novocure Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Novocure Ltd data using free add-ons & libraries
Get Novocure Ltd Fundamental Data
Novocure Ltd Fundamental data includes:
- Net Revenue: 725 M
- EBITDA: -103 490 000
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-10-29
- EPS/Forecast: -0.21
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Novocure Ltd News
New
Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stock
Have you assessed how the international operations of NovoCure (NVCR) performed in the quarter ended September 2026? For this oncology drug developer, possessing an expansive global footprint, parsing...
NovoCure (NVCR) Q3 Results Spark Margin Turn Debate
NovoCure came into this Q3 2026 report with a bruised chart, down double digits over the past month, yet the stock barely moved today, up just 0.3% around US$13. That muted reaction sits awkwardly aga...
NovoCure Stock Is In Focus After Earnings Beat And Slower Optune Pax Launch
NovoCure reported third quarter 2026 net revenue of US$193.4 million and a reduced net loss of US$10.44 million, and raised full year 2026 revenue guidance to a range of US$736 million to US$743 milli...
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
NovoCure (NVCR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.33 per share a year ago. These figures are adjus...
Get Novocure Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.